A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
NCT04616040
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
1030
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Cancer
Interventions
DRUG:
Camrelizumab
Sponsor
Peking University